Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract: A method for curating documents, executed by a computer, includes detecting one or more themes in a document, identifying one or more user interests for a user, presenting a ranked list of the one or more themes to the user, and dynamically updating the ranked list based on user feedback. The ranked list may be ranked according to the one or more user interests. A computer program product and computer system corresponding to the above method are also disclosed herein.

Abstract: According to an embodiment of the present disclosure, an electrical device may include a substrate, an electrical element, a first barrier structure and a gas barrier layer. The substrate includes an active region and a periphery region surrounding the active region. The electrical element is disposed in the active region. The first barrier structure is disposed in the periphery region and surrounds the electrical element, wherein the first barrier structure includes a first conductive layer. The gas barrier layer covers the electrical element and the first barrier structure.

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract: This invention relates to compounds of general formula in which R1, R2, R6, U, V, W, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, pharmaceutical compositions containing such compounds and salts, and to methods of using such compounds, salts and compositions.

Abstract: A method for curating documents, executed by a computer, includes detecting one or more themes in a document, identifying one or more user interests for a user, presenting a ranked list of the one or more themes to the user, and dynamically updating the ranked list based on user feedback. The ranked list may be ranked according to the one or more user interests. A computer program product and computer system corresponding to the above method are also disclosed herein.

Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein A, L, D, R1-R15, w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract: Provided herein is a method of screening a tumour cell for resistance to a tubulin-binding agent, the method comprising detecting the expression of any one or more of class II, class III and class IVb ?-tubulin by the tumour cell, wherein the expression of any one or more of class II, class III and class IVb ?-tubulin indicates that the tumour cell has resistance or potential resistance to the tubulin-binding agent. Also provided are methods of modulating the sensitivity of a tumour cell Also provided is a method of modulating the tumorigenesis of a tumour cell.

Abstract: A lead frame strip includes a plurality of connected unit lead frames, each unit lead frame having a die paddle and a plurality of leads connected to a periphery of the unit lead frame. A semiconductor die is attached to the die paddles. A molding compound covers the unit lead frames, including the semiconductor dies. Prior to testing or other processing of the lead frame strip, a gap is etched into a region of the leads which are shared by adjacent ones of the unit lead frames. The gap extends at least mostly through the shared leads. A partial cut is made in the molding compound around the periphery of the unit lead frames prior to the subsequent processing, including below the gap in the shared leads, to electrically isolate the leads of the unit lead frames.

Abstract: A display including a plurality of display units and a plurality of holes is provided. Each of the display units includes a transparent area. Each of the holes is formed by a part of the transparent areas. At least one of the holes satisfies 2 ? ? ? ? A ? S < 8 3 ? 3 ? ? A , wherein A is an area of each of the holes and the S is a perimeter of each of the holes, and the at least one of the holes is a hole of a non-quadrilateral-type shape. These holes are arranged along a first direction in staggered arrangement, parts of projections of the holes along a second direction are overlapped with one another, and the first direction is different from the second direction.

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract: This invention relates to compounds of general formula (I), in which R1, R2, R6, U, V, W, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, pharmaceutical compositions containing such compounds and salts, and to methods of using such compounds, salts and compositions.

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract: A lead frame strip includes a plurality of connected unit lead frames, each unit lead frame having a die paddle and a plurality of leads connected to a periphery of the unit lead frame. A semiconductor die is attached to the die paddles. A molding compound covers the unit lead frames, including the semiconductor dies. Prior to testing or other processing of the lead frame strip, a gap is etched into a region of the leads which are shared by adjacent ones of the unit lead frames. The gap extends at least mostly through the shared leads. A partial cut is made in the molding compound around the periphery of the unit lead frames prior to the subsequent processing, including below the gap in the shared leads, to electrically isolate the leads of the unit lead frames.

Abstract: Enantiomerically pure compound of formula 1 are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.

Abstract: The disclosure provides an electrowetting display device. The electrowetting display device includes a first substrate and a second substrate disposed to each other. A first electrode layer may dispose on the first substrate. A second electrode layer may dispose on the second substrate. A hydrophobic dielectric layer is disposed on the first electrode layer. A first pixel rib is disposed on the first substrate. A second pixel rib is disposed on the first pixel rib. A water contact angle of the second pixel rib may be larger than that of the first pixel rib. A first liquid and a second liquid may be disposed in between the first substrate and the second substrate.

Abstract: Enantiomerically pure compound of formula 1 are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.